Capital Fund Management (CFM)’s Nektar Therapeutics NKTR Stock Holding History

Capital Fund Management (CFM)’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-13,756	Closed	-$784K	–	1575
2022 Q2	$784K	Buy	+13,756	New	+$868K	0.01%	1152
2020 Q4	–	Sell	-1,540	Closed	-$383K	–	1474
2020 Q3	$383K	Sell	1,540 -1,279	-45%	-$402K	﹤0.01%	1083
2020 Q2	$979K	Buy	+2,819	New	+$880K	0.02%	698
2018 Q4	–	Sell	-47,143	Closed	-$28.5M	–	2102
2018 Q3	$43.1M	Buy	+47,143	New	+$40.2M	0.24%	90
2018 Q2	–	Sell	-563	Closed	-$649K	–	2193
2018 Q1	$897K	Buy	+563	New	+$725K	0.01%	1277
2016 Q4	–	Sell	-5,933	Closed	-$1.53M	–	1791
2016 Q3	$1.53M	Buy	+5,933	New	+$1.53M	0.01%	839
2016 Q1	–	Sell	-747	Closed	-$189K	–	1745
2015 Q4	$189K	Buy	+747	New	+$154K	﹤0.01%	1458
2015 Q3	–	Sell	-8,045	Closed	-$1.51M	–	1583
2015 Q2	$1.51M	Buy	+8,045	New	+$1.38M	0.02%	713
2013 Q3	–	Sell	-2,167	Closed	-$375K	–	1791
2013 Q2	$375K	Buy	+2,167	New	+$332K	0.01%	1076

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capital Fund Management (CFM)'s NKTR Position: Q3 2022 in Review

Capital Fund Management (CFM) sold out of Nektar Therapeutics (NKTR) in Q3 2022, closing a stake of 13,756 shares — an estimated $784K sold.

Capital Fund Management (CFM) first reported a position in NKTR in Q2 2013 and held it in 9 quarters. The position peaked at $43.1M in Q3 2018. 230 funds tracked by Wall St. Rank hold NKTR as of Q3 2022.

Capital Fund Management (CFM) reported no remaining Nektar Therapeutics position as of Q3 2022 after selling out during the quarter.
Capital Fund Management (CFM) sold 13,756 Nektar Therapeutics shares in Q3 2022, an estimated $784K.
Capital Fund Management (CFM) first reported a position in Nektar Therapeutics in Q2 2013 and held it in 9 quarters.
Capital Fund Management (CFM)'s Nektar Therapeutics position peaked at $43.1M in Q3 2018.
230 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2022.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2022, filed 14 Nov 2022.